ArticlePatient preference and adherence2025
Unlocking the Keys to Swift HIV Treatment: A Qualitative Exploration of Rapid Antiretroviral Therapy Initiation Among People Living with HIV in China.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effect of rapid antiretroviral therapy initiation on loss to follow-up, virologic failure, and immunologic failure among people living with HIV under the treat-all policy in China: a retrospective cohort study (2016-2023).Frontiers in medicine · 2026Article
- Analysis of factors influencing rapid treatment initiation decisions among people living with HIV: focusing on the role of social support.Frontiers in public health · 2026Article
- HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019-2023.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rapid initiation of antiretroviral therapy (ART) is beneficial for people living with HIV (PLWH) to achieve the virological suppression and decrease the risk of HIV transmission. However, the implementation of rapid ART varies across the world. Objective: This study aims to understand the influencing factors of rapid start of ART in PLWH in Liangshan Prefecture, where the HIV epidemic is severe and is a key area for HIV prevention and control in China, to provide information for making effective interventions in China and elsewhere. Methods: A phenomenological study with semi-structured in-depth interviews was conducted in Liangshan Prefecture, Sichuan Province, China, from April 2024 to May 2024. Data were analyzed by using the Colaizzi's seven-step method. Results: Participants (n = 27) aged 14-55 were interviewed (14 males and 13 females). Participants initiated ART at a median time of 29 days. 15 participants initiated ART within 30 days of HIV diagnosis, but no one initiated ART within seven days of HIV diagnosis. Three themes and nine sub-themes affecting the rapid start of ART were identified: capacity factors (physical condition, disease knowledge, psychological resilience); opportunity factors (affordability of medicines, policy timeliness, diagnosis disclosure and social support, attitudes of healthcare workers); and motivation factors (family roles, benefit perception of ART). Conclusion: Influencing factors affecting the rapid initiation of ART in PLWH were complex. Healthcare providers should strengthen the knowledge education from the perspective of PLWH, pay more attention to the psychological changes after they are diagnosed with HIV infection, improve their social support network, alleviate their treatment burden, help them make scientific decisions, and promote the implementation of rapid initiation of ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.